[ad_1]
Stifel Nicolaus reduced their target price on Accenture from $355.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday.
[ad_2]
Source link
[ad_1] Nuveen LLC acquired a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) in the first quarter, according…
[ad_1] Westwood Holdings Group Inc. purchased a new stake in Vertiv Holdings Co. (NYSE:VRT – Free Report) during the first…
[ad_1] The technology sector is making waves again, both in the stock market and on the political spectrum. This time around,…